These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 7738643)
1. Anti-chelate antibodies after intraperitoneal yttrium-90-labeled monoclonal antibody immunoconjugates for ovarian cancer therapy. Kosmas C; Maraveyas A; Gooden CS; Snook D; Epenetos AA J Nucl Med; 1995 May; 36(5):746-53. PubMed ID: 7738643 [TBL] [Abstract][Full Text] [Related]
2. Development of humoral immune responses against a macrocyclic chelating agent (DOTA) in cancer patients receiving radioimmunoconjugates for imaging and therapy. Kosmas C; Snook D; Gooden CS; Courtenay-Luck NS; McCall MJ; Meares CF; Epenetos AA Cancer Res; 1992 Feb; 52(4):904-11. PubMed ID: 1737353 [TBL] [Abstract][Full Text] [Related]
3. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies. Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230 [TBL] [Abstract][Full Text] [Related]
4. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re. Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657 [TBL] [Abstract][Full Text] [Related]
5. Intraperitoneal 131I- and 90Y-labelled monoclonal antibodies for ovarian cancer: pharmacokinetics and normal tissue dosimetry. Stewart JS; Hird V; Snook D; Sullivan M; Myers MJ; Epenetos AA Int J Cancer Suppl; 1988; 3():71-6. PubMed ID: 3209303 [TBL] [Abstract][Full Text] [Related]
6. Indium-111- and yttrium-90-labeled human monoclonal immunoglobulin M targeting of human ovarian cancer in mice. Borchardt PE; Quadri SM; Freedman RS; Vriesendorp HM J Nucl Med; 1998 Mar; 39(3):476-84. PubMed ID: 9529295 [TBL] [Abstract][Full Text] [Related]
7. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity. Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726 [TBL] [Abstract][Full Text] [Related]
9. Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: results of a phase I clinical trial. DeNardo SJ; Kramer EL; O'Donnell RT; Richman CM; Salako QA; Shen S; Noz M; Glenn SD; Ceriani RL; DeNardo GL J Nucl Med; 1997 Aug; 38(8):1180-5. PubMed ID: 9255145 [TBL] [Abstract][Full Text] [Related]
10. Human anti-mouse IgM and IgG responses in ovarian cancer patients after radioimmunotherapy with 90Y-muHMFG1. Oei AL; Sweep FC; Geurts-Moespot A; van Tienoven D; Von Mensdorff-Pouilly S; Thomas CM; Massuger LF Anticancer Res; 2008; 28(5A):2721-5. PubMed ID: 19035301 [TBL] [Abstract][Full Text] [Related]
11. Radioimmunotherapy of human colorectal carcinoma xenografts using 90Y-labeled monoclonal antibody CO17-1A prepared by two bifunctional chelate techniques. Lee YC; Washburn LC; Sun TT; Byrd BL; Crook JE; Holloway EC; Steplewski Z Cancer Res; 1990 Aug; 50(15):4546-51. PubMed ID: 2164441 [TBL] [Abstract][Full Text] [Related]
12. Similarities and differences in 111In- and 90Y-labeled 1B4M-DTPA antiTac monoclonal antibody distribution. Carrasquillo JA; White JD; Paik CH; Raubitschek A; Le N; Rotman M; Brechbiel MW; Gansow OA; Top LE; Perentesis P; Reynolds JC; Nelson DL; Waldmann TA J Nucl Med; 1999 Feb; 40(2):268-76. PubMed ID: 10025834 [TBL] [Abstract][Full Text] [Related]
13. A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. Wong JY; Shibata S; Williams LE; Kwok CS; Liu A; Chu DZ; Yamauchi DM; Wilczynski S; Ikle DN; Wu AM; Yazaki PJ; Shively JE; Doroshow JH; Raubitschek AA Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5842-52. PubMed ID: 14676105 [TBL] [Abstract][Full Text] [Related]
14. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model. Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and toxicity of an yttrium-90-CITC-DTPA-HMFG1 radioimmunoconjugate for intraperitoneal radioimmunotherapy of ovarian cancer. Maraveyas A; Snook D; Hird V; Kosmas C; Meares CF; Lambert HE; Epenetos AA Cancer; 1994 Feb; 73(3 Suppl):1067-75. PubMed ID: 8306249 [TBL] [Abstract][Full Text] [Related]
16. Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies: critical factors in determining in vivo survival and organ toxicity. Kozak RW; Raubitschek A; Mirzadeh S; Brechbiel MW; Junghans RP; Gansow OA; Waldmann TA Cancer Res; 1989 May; 49(10):2639-44. PubMed ID: 2785435 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies. Camera L; Kinuya S; Garmestani K; Wu C; Brechbiel MW; Pai LH; McMurry TJ; Gansow OA; Pastan I; Paik CH J Nucl Med; 1994 May; 35(5):882-9. PubMed ID: 8176477 [TBL] [Abstract][Full Text] [Related]